Perlmutter Cancer Center
Professor, Department of Biochemistry and Molecular Pharmacology
The central goal of our research effort is to control biology at molecular levels using synthetic proteins. Our main focus is the design and engineering of new protein function, in particular, target binding, a fundamental function underlying most biological events. Our research is multi-disciplinary, integrating rational design, directed evolution, structural and cellular biology.
By utilizing "synthetic binding proteins" as uniquely powerful tools, we achieve high-precision control of cellular regulatory machineries, particularly those governed by allostery and/or post-translational modification, e.g. phospho-signaling, epigenetics and membrane proteins.
As Director of Cancer Biologics at the Perlmutter Cancer Center, we are developing cancer therapeutics and novel tools for cancer biology investigation.
Director, Cancer Biologics
PhD from University of Tokyo
The Scripps Research Institute, Molecular Biophysics
Nature. 2021 Jul; 595(7867):404-408
Cell reports. 2022 02 08; 38(6):110322
Journal of molecular biology. 2021 Dec 24; 167402
Nature communications. 2021 May 11; 12(1):2656
Nature. 2022 10; 610(7932):547-554
Proceedings of the National Academy of Sciences of the United States of America (PNAS). 2022 Oct 25; 119(43):e2204481119
Nature. 2018 01 25; 553(7689):526-529
Nature chemical biology. 2017 Jan; 13(1):62-68